Skip to content

Innovative Medicine
healthcare areas

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again

      U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

      First and only drug releasing system to provide extended local delivery of a cancer medication into the bladder, with 82 percent of patients achieving complete response without the need for reinduction1 Potential practice-changing treatment for certain patients with BCG-unresponsive non-muscle invasive bladder cancer who have limited options before possible bladder removal

      Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

      21 abstracts from across the Company’s portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and schizophrenia New Phase 3 data demonstrate the safety and efficacy of adjunctive seltorexant compared to quetiapine XR in major depressive disorder with insomnia symptoms

      Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis

      Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sites Submission underscores potential to shift the treatment paradigm for moderate-to-severe plaque psoriasis patients with the standout combination of complete skin clearance, a favorable safety profile, and simplicity of a once daily pill

      Areas of focus

      Our transformational medicines are developed with rigorous science and unwavering compassion to provide the greatest impact for patients. We create new and groundbreaking medicines to change the future of health. Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way.
      At Johnson & Johnson, we are leading where medicine is going, with a relentless focus on bringing transformational medical innovation to patients who are waiting. Our team’s deep expertise and global reach are helping us reimagine how devastating diseases are treated and cured, delivering hope and better care for millions of patients and their families around the world.
      Jennifer L. Taubert
      Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson

      Resources

      Our innovations

      Newsroom

      The latest news, information, and stories from Johnson & Johnson Innovative Medicine.

      Additional links